154 related articles for article (PubMed ID: 38329392)
21. Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.
Stein MK; Williard FW; Xiu J; Tsao MW; Martin MG; Deschner BW; Dickson PV; Glazer ES; Yakoub D; Shibata D; Grothey AF; Philip PA; Hwang JJ; Shields AF; Marshall JL; Korn WM; Lenz HJ; Deneve JL
J Surg Oncol; 2020 Jun; 121(8):1320-1328. PubMed ID: 32166754
[TBL] [Abstract][Full Text] [Related]
22. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
23. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
[TBL] [Abstract][Full Text] [Related]
24. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ
JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531
[TBL] [Abstract][Full Text] [Related]
25. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
28. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis.
Ramadan M; Alfayea T; Alsofyani A; Alyabsi M; Alhusseini N; Algarni AS
Cancer Treat Res Commun; 2022; 33():100632. PubMed ID: 36088745
[TBL] [Abstract][Full Text] [Related]
29. Colic and rectal tumors with peritoneal metastases treated with cytoreductive surgery and HIPEC: One homogeneous condition or two different diseases? A systematic review and meta-analysis.
Tonello M; Sommariva A; Pirozzolo G; Mattara G; Pilati P
Eur J Surg Oncol; 2019 Nov; 45(11):2003-2008. PubMed ID: 31217079
[TBL] [Abstract][Full Text] [Related]
30. Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.
Hamed AB; Shuai Y; Derby J; Holtzman MP; Ongchin M; Bartlett DL; Pingpank JF; Pai R; Singhi A; Choudry HA
Ann Surg Oncol; 2023 Jul; 30(7):4459-4470. PubMed ID: 37085655
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence.
Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V
Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409
[TBL] [Abstract][Full Text] [Related]
32. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
34. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
36. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
[TBL] [Abstract][Full Text] [Related]
38. Differences in the distribution of peritoneal metastases in right- versus left-sided colon cancer on MRI.
Engbersen MP; Nerad E; Rijsemus CJV; Buffart T; Beets-Tan RGH; Aalbers AGJ; Kok NFM; Lahaye MJ
Abdom Radiol (NY); 2022 Feb; 47(2):530-537. PubMed ID: 34894278
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.
Baratti D; Kusamura S; Niger M; Perrone F; Milione M; Cattaneo L; Guaglio M; Bartolini V; Pietrantonio F; Deraco M
Ann Surg Oncol; 2021 Jun; 28(6):3332-3342. PubMed ID: 32974694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]